Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration
2016
Toxicities of chimeric antigen receptor T cells: recognition and management
2016
Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors
2022 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors
2017
ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
2023 StandoutNobel
Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma
2019
Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions
2021 StandoutNobel
FLT3 inhibitors in acute myeloid leukemia
2018
mRNA therapeutics in cancer immunotherapy
2021
Systematic development of ionizable lipid nanoparticles for placental mRNA delivery using a design of experiments approach
2023 StandoutNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Reading the glyco-code: New approaches to studying protein–carbohydrate interactions
2022 StandoutNobel
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Delivery strategies of cancer immunotherapy: recent advances and future perspectives
2019
Engineering precision nanoparticles for drug delivery
2020 Standout
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
2020
Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer
2017
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Clinical lessons learned from the first leg of the CAR T cell journey
2019
CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
2020
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
2020 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Cytokine release syndrome
2018
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 StandoutNobel
Viral noncoding RNAs: more surprises
2015
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
2018 StandoutNobel
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
The tumor microenvironment
2020 Standout
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Engineered T cells: the promise and challenges of cancer immunotherapy
2016
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Programming CAR-T cells to kill cancer
2018
CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy
2021
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
2022 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Nasopharyngeal carcinoma
2015 Standout
CAR T‐cell immunotherapy: The path from the by‐road to the freeway?
2015
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Fusobacterium nucleatum Promotes Colorectal Carcinogenesis by Modulating E-Cadherin/β-Catenin Signaling via its FadA Adhesin
2013 Standout
CAR-T cell therapy: current limitations and potential strategies
2021 Standout
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
2020 Standout
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Endogenous microRNA sponges: evidence and controversy
2016 Standout
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
2017
De novo design of tyrosine and serine kinase-driven protein switches
2021 StandoutNobel
Microbiome and Malignancy
2011
Clinical relevance of tumour-associated macrophages
2022
A systems approach to infectious disease
2020
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
2022
Chimeric antigen receptor T-cell therapies for lymphoma
2017
Macrophages as tools and targets in cancer therapy
2022
The human microbiome: at the interface of health and disease
2012 Standout
Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response
2018 StandoutNobel
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA–Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy
2018
Computational design of a synthetic PD-1 agonist
2021 StandoutNobel
Genome-Wide DNA Methylation as an Epigenetic Consequence of Epstein-Barr Virus Infection of Immortalized Keratinocytes
2014
Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies
2019
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
2019
Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis
2017
The emerging role of immune checkpoint based approaches in AML and MDS
2017 StandoutNobel
Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy
2016
Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies
2022
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Chimeric Antigen Receptor Therapy
2018 Standout
Cancer Immunotherapy Using CAR‐T Cells: From the Research Bench to the Assembly Line
2017
In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update
2020
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
2017
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Works of Michael Klichinsky being referenced
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
2017
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
2016
Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms
2016
Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model
2016
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
2015
An Atlas of the Epstein-Barr Virus Transcriptome and Epigenome Reveals Host-Virus Regulatory Interactions
2012
Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
2021
EBV Latency Types Adopt Alternative Chromatin Conformations
2011
273. Genome Editing Using CRISPR-Cas9 to Increase the Therapeutic Index of Antigen-Specific Immunotherapy in Acute Myeloid Leukemia
2016
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia
2015
Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia
2016
Ruxolitinib Prevents Cytokine Release Syndrome after Car T-Cell Therapy Without Impairing the Anti-Tumor Effect in a Xenograft Model
2017